The impact of oral probiotics on vaginal Group B Streptococcal colonization rates on Group B Streptococcus (GBS)-positive pregnant women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211012052737N1

Enrollment

Registered

2021-11-02

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Streptococcus group B in pregnant women. Streptococcus B carrier state complicating pregnancy

Interventions

Intervention 1: Intervention group: Pregnant women will receive one 500 mg Familact capsule for 1 month. The supplement constituents 7 strains ( Lactobacillus Casei, Lactobacillus Rhamnosus, Streptoco

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patient consent to participate in this study Pregnant women over 18 years of age who are diagnosed with GBS based on physical examination, clinical and laboratory signs. Having a positive culture of vaginal / rectal secretions for group B streptococci Gestational age 36 weeks and less

Exclusion criteria

Exclusion criteria: Preeclampsia or gestational diabetes or other diseases Termination of pregnancy earlier than 38 weeks of gestation Absolute bed rest of the patient Taking antibiotics during the intervention and one week before it

Design outcomes

Primary

Measure	Time frame
Frequency of group B streptococcus. Timepoint: 1 month after intervention. Method of measurement: Positive culture test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Tooti

Esfahan University of Medical Sciences

drelhamtooty.inf@gmail.com+98 31 3620 2086

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026